BacteremiaPhase 4NCT02150031
Bacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols
A Phase 4 study testing 0.2% Chlorhexidine, 1% Chlorhexidine and Blood extraction in people with Bacteremia and Tooth Extraction Status Nos, run by University of Santiago de Compostela at 2 sites in 2 countries.
Trial summary
The first time the American Heart Association (AHA) suggested that disinfection of the gingival sulcus be performed as a complement to antibiotic prophylaxis in patients considered to be at risk of Infective endocarditis (IE) was in their protocol for the prevention of IE published in 1977. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Bacteremia, Tooth Extraction Status Nos
- What is being tested?
- 0.2% Chlorhexidine, 1% Chlorhexidine and Blood extraction
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 208 participants
- Where
- 2 sitesin 2 countries
- Study dates
- Dec 2010to Jun 2012
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- with need for dental extraction
Who cannot join
- patients under 18 years of age
- antibiotic treatment in the previous three months
- routine use of oral antiseptics
- any type of congenital or acquired immunodeficiency or other disease that could favour the onset of infection or haemorrhagic complications
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Portugal1 site
Department of Stomatology and Maxillofacial Surgery of the Santo Antonio General Hospital
Porto, Porto District, 4099-001 PORTO
Spain1 site
Department of Stomatology University of Santiago de Compostela
Santiago de Compostela, Galicia/A Coruña, 15782
About this study
Official title: Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols
The first time the American Heart Association (AHA) suggested that disinfection of the gingival sulcus be performed as a complement to antibiotic prophylaxis in patients considered to be at risk of Infective endocarditis (IE) was in their protocol for the prevention of IE published in 1977. This practice was included by the AHA and adopted by other expert committees such as the British Society for Antimicrobial Chemotherapy (BSAC) in subsequent prophylactic regimens. In 1992, the BSAC specified the presentation and concentration of chlorhexidine (CHX) that should be used before starting the dental procedure: 1% gel at the gingival margin or 0.2% mouthwash for five minutes. In 1997, the AHA recognised the need to use antiseptic mouthwashes (CHX or povidone iodine) prior to dental manipulations, although they recommended against the use of gingival irrigators and against the continuous use of antiseptics in order to avoid the selection of resistant micro-organisms In 2006, the BSAC recommended a single mouthwash with 0.2% CHX gluconate (10 ml for 1 minute) before performing dental procedures associated with bacteraemia in patients at risk of IE. In contrast, in 2007, the AHA recommended against the use of any antiseptic prophylaxis protocol.
In 2008, the National Institute for Health and Clinical Excellence of the United Kingdom recently performed a systematic review of the antimicrobial prophylaxis protocols for IE and reported that: "Oral chlorhexidine used as an oral rinse does not significantly reduce the level of bacteraemia following dental procedures". This conclusion was reached after analysis of numerous studies on the efficacy of prophylaxis with CHX for the prevention of post-dental manipulation bacteraemia. However, those studies presented significant methodological differences not only in the dental procedures performed, but also in the concentration of CHX applied and the method of application of the antiseptic solution (mouthwash and/or irrigation), making comparison of the results of the different series difficult.
Read more
There are few studies that have analysed the efficacy of the mouthwash of 0.2% CHX (the concentration recommended by the BSAC) in the prevention of post-extraction bacteraemia. Only one study analysed the combination of local irrigation and mouthwash with chlorhexidine before dental extraction, but with a really lower concentration of CHX, only 0.02%.
The objective of this study is to investigate the prevalence, duration and aetiology of bacteraemia secondary to a single tooth extraction after prophylaxis with different CHX protocols.
Read the detailed description
The study group will be formed of patients undergoing tooth extraction under local anaesthesia in the Department of Stomatology and Maxillofacial Surgery of the Santo Antonio General Hospital (Oporto, Portugal).The following exclusion criteria will be applied: patients under 18 years of age; antibiotic treatment in the previous three months; routine use of oral antiseptics; and any type of congenital or acquired immunodeficiency or other disease that can favour the onset of infection or haemorrhagic complications. Applying these criteria and after a statistic power test, the sample will be 208 patients. The select patients will be attributed randomly a number of participation and they will be distributed into four groups:
- Control Group: 52 patients who will use no prophylactic chlorhexidine (CHX) regimen.
- CHX mouthwash group (CHX-MW group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute, BSAC recommendations) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain) before the tooth extraction.
- CHX mouthwash/subgingival irrigation group (CHX-MW/SUB_IR group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who then will undergo subgingival irrigation with 1% CHX on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (CIS) (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).
- CHX mouthwash/supragingival irrigation group (CHX-MW/SUPRA_IR group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who then will undergo supragingival irrigation with 1% CHX on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.
The mouthwash and subgingival or supragingival irrigation will be performed before injection of the local anaesthetic.
After recording the sex and age of each patient, a single dentist will perform an intraoral examination 2 days before the intervention, collecting the following information: plaque deposits (simplified Greene and Vermillion oral hygiene index) , calculus deposits (Ramfjord calculus index), presence of gingival bleeding (Löe and Silness gingival index), depth of periodontal pockets (Ramfjord index), degree of tooth mobility (Ramfjord tooth mobility index), number of caries (including root remnants), and presence of submucosal abscesses, fistulae and periapical foci detected clinically and/or radiologically. Each patient will be assigned an overall oral health status using a scale designed by the authors and published previously; the scale incorporates dental and periodontal health criteria.
Local anaesthesia will be administered to all patients using conventional techniques (regional block and/or infiltration). The anaesthetic will be lidocaine plus adrenaline (1:100,000) and not more than 2 cartridges in any patient.
The prevalence of baseline bacteraemia will be determined by collection of a peripheral venous blood sample (10 ml) from each patient before performing any manipulation. The prevalence of bacteraemia secondary to a mouthwash and subgingival or supragingival irrigation will be determined by the collection of a peripheral blood sample (10 ml) 30 seconds after each of these actions. Further samples (10 ml) will be drawn 30 seconds and 15 minutes after completion of the tooth extraction in order to determine the prevalence and duration of post-extraction bacteraemia.
Intravenous access will established using an 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) inserted in the antecubital fossa or dorsum of the hand after disinfection of the area with alcohol and povidone iodine. The catheter will be flushed with 3 ml of saline after each extraction and the first 2 ml of blood was discarded. Equal volumes of each sample will be inoculated into two bottles containing aerobic and anaerobic culture media (Bactec Plus, Becton Dickinson), and the bottles will be immediately transferred to the laboratory. The whole process of manipulation and transport of the samples will be performed in accordance with the recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology.
The blood culture bottles into which the blood samples will be injected and processed in the Bactec 9240 (Becton Dickinson). Gram stain will be performed on all positive cultures. The positive aerobic blood cultures will be subcultured on blood agar and chocolate agar in an atmosphere with 5%-10% CO2, and on MacConkey agar under aerobic conditions. The same protocol will be used for the positive anaerobic blood cultures but include subculture on Schaedler agar and incubation under anaerobic conditions. The bacteria isolated will be identified using the battery of biochemical tests provided by the Vitek system (bioMérieux Inc., Hazelwood, Missouri, USA) for gram-positive bacteria, Neisseria spp./Haemophilus spp. and obligate anaerobic bacteria. Applying the Ruoff criteria, Streptococcus viridans will be classified into five groups: mutans, salivarius, bovis, anginosus and mitis.
- Conditions
- Bacteremia, Tooth Extraction Status Nos
- Being tested
- 0.2% Chlorhexidine, 1% Chlorhexidine, Blood extraction, Lidocaine plus adrenaline, Tooth extraction
- Keywords
- prevention and control, chlorhexidine, therapeutic irrigation, mouthwashes, culture
- Medical subject headings
- Bacteremia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
0.2% ChlorhexidineDrug
Also called OraldinePerio, Chlorhexidine 0.2%
mouthwash with 10 ml for 1 minute
1% ChlorhexidineDrug
Also called Normosept 1g/100ml sloution, Chlorhexidine 1%
subgingival irrigation
1% ChlorhexidineDrug
Also called Normosept 1g/100ml solution, Chlorhexidine 1%
supragingival irrigation
Blood extractionProcedure or surgery
Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
Lidocaine plus adrenalineDrug
Also called anaesthesia
local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
Tooth extractionProcedure or surgery
dental extraction
| Study group | Role | What they receive |
|---|---|---|
| Control | Other | * Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
* No prophylactic Chlorhexidine regimen.
* Local anesthesia with lidocaine plus adrenaline (1:100,000).
* Tooth extraction. Receives: Procedure: Blood extraction; Drug: Lidocaine plus adrenaline; Procedure: Tooth extraction |
| CHX-Mouthwash | Active comparator | * Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).
* Local anesthesia with lidocaine plus adrenaline (1:100,000).
* Tooth extraction. Receives: Drug: 0.2% Chlorhexidine; Procedure: Blood extraction; Drug: Lidocaine plus adrenaline; Procedure: Tooth extraction |
| CHX-MW/SUB_IR | Active comparator | * Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).
* Local anesthesia with lidocaine plus adrenaline (1:100,000).
* Tooth extraction. Receives: Drug: 0.2% Chlorhexidine; Drug: 1% Chlorhexidine; Procedure: Blood extraction; Drug: Lidocaine plus adrenaline; Procedure: Tooth extraction |
| CHX-MW/SUPRA_IR | Active comparator | * Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.
* Local anesthesia with lidocaine plus adrenaline (1:100,000).
* Tooth extraction. Receives: Drug: 0.2% Chlorhexidine; Drug: 1% Chlorhexidine; Procedure: Blood extraction; Drug: Lidocaine plus adrenaline; Procedure: Tooth extraction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in the prevalence of bacteraemia
Presence of bacteria and how long it lasts in the blood stream.
Measured: before and 30 seconds after the antiseptic aplication and 30 seconds and 15 minutes after dental extraction.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2014 (estimated)
- Study startDec 2010
- Primary completionMay 2012
- Study completionJun 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for BacteremiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 208 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Santiago de Compostela
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Inmaculada Tomas, University of Santiago de Compostela
- Investigators
- Inmaculada Tomas, Principal investigator, Senior lecturer at University of Santiago de Compostela
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02150031
- Sponsor's protocol ID
- 2008/202 CHX bacteraemia
- Status last verified
- May 2014
- First submitted
- 16 May 2014
- Last updated
- 29 May 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Tomas I, Alvarez M, Limeres J, Tomas M, Medina J, Otero JL, Diz P. Effect of a chlorhexidine mouthwash on the risk of postextraction bacteremia. Infect Control Hosp Epidemiol. 2007 May;28(5):577-82. doi: 10.1086/516663. Epub 2007 Apr 5.
PubMed 17464918Tomas I, Alvarez M, Limeres J, Potel C, Medina J, Diz P. Prevalence, duration and aetiology of bacteraemia following dental extractions. Oral Dis. 2007 Jan;13(1):56-62. doi: 10.1111/j.1601-0825.2006.01247.x.
PubMed 17241431Benitez-Paez A, Alvarez M, Belda-Ferre P, Rubido S, Mira A, Tomas I. Detection of transient bacteraemia following dental extractions by 16S rDNA pyrosequencing: a pilot study. PLoS One. 2013;8(3):e57782. doi: 10.1371/journal.pone.0057782. Epub 2013 Mar 4.
PubMed 23469240Pineiro A, Tomas I, Blanco J, Alvarez M, Seoane J, Diz P. Bacteraemia following dental implants' placement. Clin Oral Implants Res. 2010 Sep;21(9):913-8. doi: 10.1111/j.1600-0501.2010.01928.x.
PubMed 20701619Barbosa M, Prada-Lopez I, Alvarez M, Amaral B, de los Angeles CD, Tomas I. Post-tooth extraction bacteraemia: a randomized clinical trial on the efficacy of chlorhexidine prophylaxis. PLoS One. 2015 May 8;10(5):e0124249. doi: 10.1371/journal.pone.0124249. eCollection 2015.
PubMed 25955349
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols
- ClinicalTrials.gov ID
- NCT02150031
- Acronym / sponsor ID
- 2008/202 CHX bacteraemia
- Conditions
- Bacteremia, Tooth Extraction Status Nos
- Keywords
- prevention and control, chlorhexidine, therapeutic irrigation, mouthwashes, culture
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 208 participants (actual)
- Lead sponsor
- University of Santiago de CompostelaUniversity, hospital or other
- Study start
- Dec 2010
- Primary completion
- May 2012 (actual)
- Study completion
- Jun 2012 (actual)
- First posted
- 29 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The first time the American Heart Association (AHA) suggested that disinfection of the gingival sulcus be performed as a complement to antibiotic prophylaxis in patients considered to be at risk of Infective endocarditis (IE) was in their protocol for the prevention of IE published in 1977. This practice was included by the AHA and adopted by other expert committees such as the British Society for Antimicrobial Chemotherapy (BSAC) in subsequent prophylactic regimens. In 1992, the BSAC specified the presentation and concentration of chlorhexidine (CHX) that should be used before starting the dental procedure: 1% gel at the gingival margin or 0.2% mouthwash for five minutes. In 1997, the AHA recognised the need to use antiseptic mouthwashes (CHX or povidone iodine) prior to dental manipulations, although they recommended against the use of gingival irrigators and against the continuous use of antiseptics in order to avoid the selection of resistant micro-organisms In 2006, the BSAC recommended a single mouthwash with 0.2% CHX gluconate (10 ml for 1 minute) before performing dental procedures associated with bacteraemia in patients at risk of IE. In contrast, in 2007, the AHA recommended against the use of any antiseptic prophylaxis protocol.
In 2008, the National Institute for Health and Clinical Excellence of the United Kingdom recently performed a systematic review of the antimicrobial prophylaxis protocols for IE and reported that: "Oral chlorhexidine used as an oral rinse does not significantly reduce the level of bacteraemia following dental procedures". This conclusion was reached after analysis of numerous studies on the efficacy of prophylaxis with CHX for the prevention of post-dental manipulation bacteraemia. However, those studies presented significant methodological differences not only in the dental procedures performed, but also in the concentration of CHX applied and the method of application of the antiseptic solution (mouthwash and/or irrigation), making comparison of the results of the different series difficult.
There are few studies that have analysed the efficacy of the mouthwash of 0.2% CHX (the concentration recommended by the BSAC) in the prevention of post-extraction bacteraemia. Only one study analysed the combination of local irrigation and mouthwash with chlorhexidine before dental extraction, but with a really lower concentration of CHX, only 0.02%.
The objective of this study is to investigate the prevalence, duration and aetiology of bacteraemia secondary to a single tooth extraction after prophylaxis with different CHX protocols.
Detailed description
The study group will be formed of patients undergoing tooth extraction under local anaesthesia in the Department of Stomatology and Maxillofacial Surgery of the Santo Antonio General Hospital (Oporto, Portugal).The following exclusion criteria will be applied: patients under 18 years of age; antibiotic treatment in the previous three months; routine use of oral antiseptics; and any type of congenital or acquired immunodeficiency or other disease that can favour the onset of infection or haemorrhagic complications. Applying these criteria and after a statistic power test, the sample will be 208 patients. The select patients will be attributed randomly a number of participation and they will be distributed into four groups:
- Control Group: 52 patients who will use no prophylactic chlorhexidine (CHX) regimen.
- CHX mouthwash group (CHX-MW group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute, BSAC recommendations) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain) before the tooth extraction.
- CHX mouthwash/subgingival irrigation group (CHX-MW/SUB_IR group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who then will undergo subgingival irrigation with 1% CHX on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (CIS) (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).
- CHX mouthwash/supragingival irrigation group (CHX-MW/SUPRA_IR group): 52 patients who will perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who then will undergo supragingival irrigation with 1% CHX on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.
The mouthwash and subgingival or supragingival irrigation will be performed before injection of the local anaesthetic.
After recording the sex and age of each patient, a single dentist will perform an intraoral examination 2 days before the intervention, collecting the following information: plaque deposits (simplified Greene and Vermillion oral hygiene index) , calculus deposits (Ramfjord calculus index), presence of gingival bleeding (Löe and Silness gingival index), depth of periodontal pockets (Ramfjord index), degree of tooth mobility (Ramfjord tooth mobility index), number of caries (including root remnants), and presence of submucosal abscesses, fistulae and periapical foci detected clinically and/or radiologically. Each patient will be assigned an overall oral health status using a scale designed by the authors and published previously; the scale incorporates dental and periodontal health criteria.
Local anaesthesia will be administered to all patients using conventional techniques (regional block and/or infiltration). The anaesthetic will be lidocaine plus adrenaline (1:100,000) and not more than 2 cartridges in any patient.
The prevalence of baseline bacteraemia will be determined by collection of a peripheral venous blood sample (10 ml) from each patient before performing any manipulation. The prevalence of bacteraemia secondary to a mouthwash and subgingival or supragingival irrigation will be determined by the collection of a peripheral blood sample (10 ml) 30 seconds after each of these actions. Further samples (10 ml) will be drawn 30 seconds and 15 minutes after completion of the tooth extraction in order to determine the prevalence and duration of post-extraction bacteraemia.
Intravenous access will established using an 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) inserted in the antecubital fossa or dorsum of the hand after disinfection of the area with alcohol and povidone iodine. The catheter will be flushed with 3 ml of saline after each extraction and the first 2 ml of blood was discarded. Equal volumes of each sample will be inoculated into two bottles containing aerobic and anaerobic culture media (Bactec Plus, Becton Dickinson), and the bottles will be immediately transferred to the laboratory. The whole process of manipulation and transport of the samples will be performed in accordance with the recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology.
The blood culture bottles into which the blood samples will be injected and processed in the Bactec 9240 (Becton Dickinson). Gram stain will be performed on all positive cultures. The positive aerobic blood cultures will be subcultured on blood agar and chocolate agar in an atmosphere with 5%-10% CO2, and on MacConkey agar under aerobic conditions. The same protocol will be used for the positive anaerobic blood cultures but include subculture on Schaedler agar and incubation under anaerobic conditions. The bacteria isolated will be identified using the battery of biochemical tests provided by the Vitek system (bioMérieux Inc., Hazelwood, Missouri, USA) for gram-positive bacteria, Neisseria spp./Haemophilus spp. and obligate anaerobic bacteria. Applying the Ruoff criteria, Streptococcus viridans will be classified into five groups: mutans, salivarius, bovis, anginosus and mitis.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control | Other | Procedure: Blood extraction, Drug: Lidocaine plus adrenaline, Procedure: Tooth extraction* Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction). * No prophylactic Chlorhexidine regimen. * Local anesthesia with lidocaine plus adrenaline (1:100,000). * Tooth extraction. |
| CHX-Mouthwash | Active comparator | Drug: 0.2% Chlorhexidine, Procedure: Blood extraction, Drug: Lidocaine plus adrenaline, Procedure: Tooth extraction* Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction). * Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain). * Local anesthesia with lidocaine plus adrenaline (1:100,000). * Tooth extraction. |
| CHX-MW/SUB_IR | Active comparator | Drug: 0.2% Chlorhexidine, Drug: 1% Chlorhexidine, Procedure: Blood extraction, Drug: Lidocaine plus adrenaline, Procedure: Tooth extraction* Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction). * Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface). * Local anesthesia with lidocaine plus adrenaline (1:100,000). * Tooth extraction. |
| CHX-MW/SUPRA_IR | Active comparator | Drug: 0.2% Chlorhexidine, Drug: 1% Chlorhexidine, Procedure: Blood extraction, Drug: Lidocaine plus adrenaline, Procedure: Tooth extraction* Blood extraction using the intravenous access 18-22 gauge "angiocath" catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction). * Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe. * Local anesthesia with lidocaine plus adrenaline (1:100,000). * Tooth extraction. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- with need for dental extraction
Key exclusion criteria (4 listed)
- patients under 18 years of age
- antibiotic treatment in the previous three months
- routine use of oral antiseptics
- any type of congenital or acquired immunodeficiency or other disease that could favour the onset of infection or haemorrhagic complications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 0.2% ChlorhexidineAlso: OraldinePerio, Chlorhexidine 0.2%mouthwash with 10 ml for 1 minute | Drug | CHX-MW/SUB_IR, CHX-MW/SUPRA_IR, CHX-Mouthwash |
| 1% ChlorhexidineAlso: Normosept 1g/100ml sloution, Chlorhexidine 1%subgingival irrigation | Drug | CHX-MW/SUB_IR |
| 1% ChlorhexidineAlso: Normosept 1g/100ml solution, Chlorhexidine 1%supragingival irrigation | Drug | CHX-MW/SUPRA_IR |
| Blood extractionBlood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction. | Procedure or surgery | CHX-MW/SUB_IR, CHX-MW/SUPRA_IR, CHX-Mouthwash, Control |
| Lidocaine plus adrenalineAlso: anaesthesialocal anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges. | Drug | CHX-MW/SUB_IR, CHX-MW/SUPRA_IR, CHX-Mouthwash, Control |
| Tooth extractiondental extraction | Procedure or surgery | CHX-MW/SUB_IR, CHX-MW/SUPRA_IR, CHX-Mouthwash, Control |
Primary outcome
Changes in the prevalence of bacteraemia
Time frame: before and 30 seconds after the antiseptic aplication and 30 seconds and 15 minutes after dental extraction.
Presence of bacteria and how long it lasts in the blood stream.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2014.
- Background: PubMed 17464918Tomas I, Alvarez M, Limeres J, Tomas M, Medina J, Otero JL, Diz P. Effect of a chlorhexidine mouthwash on the risk of postextraction bacteremia. Infect Control Hosp Epidemiol. 2007 May;28(5):577-82. doi: 10.1086/516663. Epub 2007 Apr 5.
- Background: PubMed 17241431Tomas I, Alvarez M, Limeres J, Potel C, Medina J, Diz P. Prevalence, duration and aetiology of bacteraemia following dental extractions. Oral Dis. 2007 Jan;13(1):56-62. doi: 10.1111/j.1601-0825.2006.01247.x.
- Background: PubMed 23469240Benitez-Paez A, Alvarez M, Belda-Ferre P, Rubido S, Mira A, Tomas I. Detection of transient bacteraemia following dental extractions by 16S rDNA pyrosequencing: a pilot study. PLoS One. 2013;8(3):e57782. doi: 10.1371/journal.pone.0057782. Epub 2013 Mar 4.
- Background: PubMed 20701619Pineiro A, Tomas I, Blanco J, Alvarez M, Seoane J, Diz P. Bacteraemia following dental implants' placement. Clin Oral Implants Res. 2010 Sep;21(9):913-8. doi: 10.1111/j.1600-0501.2010.01928.x.
- Derived from this study: PubMed 25955349Barbosa M, Prada-Lopez I, Alvarez M, Amaral B, de los Angeles CD, Tomas I. Post-tooth extraction bacteraemia: a randomized clinical trial on the efficacy of chlorhexidine prophylaxis. PLoS One. 2015 May 8;10(5):e0124249. doi: 10.1371/journal.pone.0124249. eCollection 2015.
Related trials for Bacteremia
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
RecruitingObservational study
Middle East Study of Infections in Patients With Hematological Malignancies
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
RecruitingPhase 4
Oral Switch in Pediatric Bloodstream Infections
Bloodstream Infection, Bacteremia Sepsis
Recruiting
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis
Infective Endocarditis (IE)
Not yet recruitingPhase 2
THiamine for Recovery In Vulnerable Early-life Infections
Meningitis, Bacteremia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Inmaculada Tomas principal investigator
Senior lecturer at University of Santiago de Compostela
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing 0.2% Chlorhexidine, 1% Chlorhexidine and Blood extraction in people with Bacteremia and Tooth Extraction Status Nos, run by University of Santiago de Compostela at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Portugal, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in the prevalence of bacteraemia (time frame: before and 30 seconds after the antiseptic aplication and 30 seconds and 15 minutes after dental extraction.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02150031, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2014.